CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study ...

Having a low hemoglobin level or a high erythropoiesis-stimulating agent (ESA) resistance index (ERI) is associated with faster decline in residual kidney function in patients undergoing peritoneal ...

Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

A systematic review and meta-analysis identified factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents (ESAs).

Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") and certain officers. The class action, filed in the United States District ...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 millionTransaction expected to close by ...

Kidneys remove waste like urea and support red blood cell production (erythropoiesis). If unhealthy, they can cause high blood pressure, fluid retention, anemia, and heart disease. Proper nutrition is ...

Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 millionCash resources and cash ...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway exte ...

Despite researchers' predictions, there was no significant difference in long-term outcomes for patients treated with ...